JNJ 40929837

Drug Profile

JNJ 40929837

Latest Information Update: 18 Aug 2015

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 23 Jun 2011 Johnson & Johnson completes a phase II trial for Asthma in United Kingdom & Germany (NCT01241422, EudraCT2010-022437-28)
  • 20 Dec 2010 Phase-II clinical trials in Asthma in United Kingdom (PO)
  • 20 Dec 2010 Phase-II clinical trials in Asthma in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top